Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis

Histopathology

Volumn 56, Issue 6, 2010, Pages 683-693

  Tretiakova, Maria S ^a   Shabani Rad, Meer T ^b   Guggisberg, Kelly ^b   Hart, John ^a   Anders, Robert A ^c   Gao, Zu Hua ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Carcinogenesis; Cirrhosis; Gene profiling; Hepatocellular carcinoma; Tissue microarray

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; WNT PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS;

EID: 77951749887     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03554.x     Document Type: Article

References (57)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 74 108.
2. Johnson PJ, Williams R. Cirrhosis and the etiology of hepatocellular carcinoma. J. Hepatol. 1987 4 140 147.
3. Harris CC. Hepatocellular carcinogenesis: recent advances and speculations. Cancer Cells 1990 2 146 148.
4. Saito I, Miyanmura T, Ohbayashi A et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1990 87 6547 6549.
5. Chen CJ, Wang LY, Lu SN et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996 24 38 42.
6. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993 18 47 53.
7. Noda K, Yoshihara H, Suzuki K et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - its relationship to alcohol drinking and the age of transfusion. Alcohol. Clin. Exp. Res. 1996 1 (Suppl. 95A 100A.
8. Ferrell LD, Crawford JM, Dhillon AP, Scheuer PJ, Nakanuma Y. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am. J. Surg. Pathol. 1993 17 1113 1123.
9. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 (5 Suppl. 1 S35 S50.
10. Nazeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinicohistopathologic study of 804 North American patients. Am. J. Clin. Pathol. 1996 105 65 75.
11. Kew MC. Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology 1989 97 136 139.
12. Okuda K, Nakashima T, Koijiro M, Kondo Y, Wada K. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989 97 140 146.
13. Tabarin A, Bioulac-Sage P, Boussarie L. Hepatocellular carcinoma developed in non-cirrhotic livers. Arch. Pathol. Lab. Med. 1987 111 174 180.
14. Smalley SR, Moertel CG, Hilton JF et al. Hepatoma in the non-cirrhotic liver. Cancer 1988 62 1414 1424.
15. Bralet MP, Regimbeau JM, Pineau P et al. Hepatocellular carcinoma occurring in a non-fibrotic liver. Hepatology 2000 32 200 204.
16. Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod. Pathol. 2005 18 1417 1423.
17. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006 25 3778 3786.
18. Edamoto Y, Hara A, Biernat W et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int. J. Cancer 2003 106 334 341.
19. Hirohashi S, Ishak KG, Kojiro M et al. Hepatocellular carcinoma. In Hamilton SR, Aaltonen LA eds. World Health Organization classification of tumor. Pathology and genetics of tumors of the digestive system.
20. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003 4 249 264.
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 2003 100 9440 9445.
22. Bali A, O'Brien PM, Edwards LS et al. Cyclin D1, p53, and p21 Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin. Cancer Res. 2004 10 5168 5177.
23. Dai Y, Bedrossian CW, Michael CW. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities. Diagn. Cytopathol. 2005 33 320 324.
24. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl Cancer Inst. 1996 88 1442 1455.
25. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996 10 1054 1072.
26. Cox LS, Lane DP. Tumor suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 1995 17 501 508.
27. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res. 1992 52 6358 6364.
28. Hosono S, Chou MJ, Lee CS, Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene 1993 8 491 496.
29. Murakami Y, Hayashi K, Hirihashi S, Sekiva T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991 51 5520 5525.
30. Tsopanomichalou M, Kouroumalis E, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human non-neoplastic hepatic lesions. Liver 1999 19 305 311.
31. Puisieux A, Lim S, Groopman J, Qzturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 1991 51 6185 6189.
32. Feitelson MA. Hepatitis B X antigen and p53 in the development of hepatocellular carcinoma. J. Hepatobiliary Pancreat. Surg. 1998 5 367 374.
33. Qin G, Su J, Ning Y, Duan X, Luo D, Lotlikar PD. p53 protein expression in patients with hepatocellular carcinoma from the high incidence area of Guangxi, Southern China. Cancer Lett. 1997 121 203 210.
34. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res. 2001 61 2085 2091.
35. Brantjes H, Barker N, Van Es J, Clevers H. TCF: lady Justice casting the final verdict on the outcome of Wnt signaling. Biol. Chem. 2002 383 255 261.
36. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J. Pathol. 2001 193 95 101.
37. Wong CM, Fan ST, Ng IO. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001 92 136 145.
38. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002 21 2593 2604.
39. Audard V, Grimber G, Elie C et al. Cholestasis is a marker for hepatocellular carcinomas displaying β-catenin mutations. J. Pathol. 2007 212 345 352.
40. Nita ME, Alves VA, Carrilho FJ, Ono-Nita SK, Mello ES, Gama-Rodrigues JJ. Molecular aspects of hepatic carcinogenesis. Rev. Inst. Med. Trop. Sao Paulo 2002 44 39 48.
41. Hsia CC, Di Bisceglie AM, Kleiner DE Jr., Farshid M, Tabor E. RB tumor suppressor gene expression in hepatocellular carcinoma from patients infected with hepatitis B virus. J. Med. Virol. 1994 44 67 73.
42. Higashitsuji H, Itoh K, Nagao T et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000 6 96 99.
43. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994 79 181 184.
44. Ho A, Dowdy SF. Regulation of G (1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev. 2002 12 47 52.
45. Deane NG, Parker MA, Aramandla R et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 2001 61 5389 5395.
46. Nishida N, Fukuda Y, Komeda T et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994 54 3107 3110.
47. Liew CT, Li HM, Lo KW et al. High frequency of p16INK4 gene alterations in hepatocellular carcinoma. Oncogene 1999 18 789 795.
48. Hui AM, Kanai Y, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21 WAF/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatolog 1997 25 575 579.
49. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. Expression and hypermethylation of p27kip1 in hepatocarcinogenesis. World J. Gastroenterol. 2005 11 4587 4591.
50. Paradis V, Youssef N, Dargere D et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol. 2001 32 327 332.
51. Lunz JG, Tsuji H, Nozaki I, Murase N, Demetris AJ. An inhibitor of cyclin-dependent kinase, stress-induced p21waf1/cip1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005 41 1262 1271.
52. Brunt EM, Walsh SN, Hayashi PH, LaBundy J, Di Bisceglie AM. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int. 2007 27 662 671.
53. Grary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 1998 28 738 743.
54. Anthony PP. Hepatocellular carcinoma: an update. Histopathology 2001 39 109 118.
55. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insight into etiology, pathogenesis and prevention from the Gambia, West Africa. Carcinogenesis 2006 27 2070 2082.
56. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med. 2003 3 573 588.
57. Iizuka N, Oka M, Yamada-Okabe H et al. Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene 2003 22 3007 3014.